Idexx Laboratories Income Statement
IDXX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Idexx Laboratories reported $4.3B in revenue and $1.1B in net income for FY2025. Revenue has grown at a 9.4% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3B | $3.9B | $3.7B | $3.4B | $3.2B | $2.7B | $2.4B | $2.2B | $2.0B | $1.8B | $1.6B | $1.5B | $1.4B | $1.3B | $1.2B |
| Cost of Revenue | $1.6B | $1.5B | $1.5B | $1.4B | $1.3B | $1.1B | $1.0B | $971.7M | $871.7M | $800.0M | $711.6M | $669.7M | $620.9M | $594.2M | $572.2M |
| Gross Profit | $2.7B | $2.4B | $2.2B | $2.0B | $1.9B | $1.6B | $1.4B | $1.2B | $1.1B | $975.4M | $890.3M | $816.1M | $756.1M | $699.1M | $646.5M |
| SG&A Expense | $404.8M | $442.3M | $335.8M | $326.2M | $309.7M | $300.8M | $261.3M | $244.9M | $220.9M | $207.0M | $182.5M | $173.9M | $157.9M | $137.6M | $129.4M |
| R&D Expense | $251.2M | $219.8M | $191.0M | $254.8M | $161.0M | $141.2M | $133.2M | $117.9M | $109.2M | $101.1M | $99.7M | $98.3M | $88.0M | $82.0M | $76.0M |
| Operating Income | $1.4B | $1.1B | $1.1B | $898.8M | $932.0M | $694.5M | $552.8M | $491.3M | $413.0M | $350.2M | $299.9M | $260.3M | $266.8M | $262.6M | $236.2M |
| Interest Expense | - | - | $41.6M | $39.9M | $29.8M | $33.1M | $31.1M | $34.7M | $37.2M | $32.0M | $29.2M | $15.4M | $5.4M | $3.8M | $3.5M |
| Income Tax | $264.7M | $222.0M | $216.1M | $180.9M | $157.8M | $79.9M | $94.4M | $80.7M | $117.8M | $99.8M | $81.0M | $64.6M | $75.5M | $82.3M | $72.7M |
| Net Income | $1.1B | $887.9M | $845.0M | $679.1M | $744.8M | $581.8M | $427.7M | $377.0M | $263.1M | $222.0M | $192.1M | $181.9M | $187.8M | $178.3M | $161.8M |
| EPS (Basic) | $10.17 | $8.12 | $8.74 | $6.82 | $4.97 | $4.34 | $3.00 | $2.47 | $2.07 | $1.82 | $1.77 | $3.24 | $2.85 | $2.45 | $2.08 |
| EPS (Diluted) | $10.06 | $8.03 | $8.60 | $6.71 | $4.89 | $4.26 | $2.94 | $2.44 | $2.05 | $1.79 | $1.74 | $3.17 | $2.78 | $2.37 | $2.01 |
| Shares Outstanding | 81.6M | 83.0M | 82.9M | 84.6M | 85.4M | 85.5M | 86.1M | 87.1M | 93.6M | 101.5M | 108.0M | 56.2M | 58.2M | 59.6M | 60.7M |
| Gross Margin | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% | 58.0% | 56.7% | 56.1% | 55.7% | 54.9% | 55.6% | 54.9% | 54.9% | 54.1% | 53.0% |
| Operating Margin | 31.6% | 28.9% | 30.0% | 26.7% | 29.0% | 25.7% | 23.0% | 22.2% | 21.0% | 19.7% | 18.7% | 17.5% | 19.4% | 20.3% | 19.4% |
| Profit Margin | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% | 17.8% | 17.0% | 13.4% | 12.5% | 12.0% | 12.2% | 13.6% | 13.8% | 13.3% |